Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of th...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmaceutica Sinica. B 2021-05, Vol.11 (5), p.1083-1097
Main Authors: Kiaie, Seyed Hossein, Sanaei, Mohammad Javad, Heshmati, Masoud, Asadzadeh, Zahra, Azimi, Iman, Hadidi, Saleh, Jafari, Reza, Baradaran, Behzad
Format: Article
Language:English
Subjects:
Clinical development
Immune checkpoint
Immunotherapy
Pancreatic cancer
Review
Tumor microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa. The latest findings on the immune checkpoints (ICPs) mediating immunosuppression in tumor microenvironment (TME) are reviewed. Different approaches for targeting ICPs in TME of pancreatic cancer (PCa) and the latest clinical applications are discussed. [Display omitted]
ISSN:2211-3835
2211-3843
DOI:10.1016/j.apsb.2020.12.011